NEW YORK (GenomeWeb News) – Clinical Data said today that the biomarker it had previously associated with response to its depression drug candidate vilazodone did not replicate its earlier success in the firm's most recent phase III study of the drug.

The Newton, Mass.-based drug developer and pharmacogenomic test maker reported positive top-line results from the second of two phase III studies of vilazodone. Clinical Data said that the drug achieved statistically significant results on the primary and secondary endpoints related to major depressive disorder.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.